Article

In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp.

Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Carrer Sant Llorenç, 21.43201 Reus, Spain.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.48). 05/2008; 52(4):1529-32. DOI: 10.1128/AAC.01097-07
Source: PubMed

ABSTRACT

The in vitro activity of amphotericin B in combination with micafungin was evaluated against 115 isolates representing seven
species of Candida. Overall, the percentages of synergistic interactions were 50% and 20% when the MIC-2 (lowest drug concentration to cause
a prominent reduction in growth) and MIC-0 (lowest drug concentration to cause 100% growth inhibition) end point criteria,
respectively, were used. Antagonism was not observed. Some of the interactions were confirmed by time-kill assays.

Download full-text

Full-text

Available from: Jose Cano

  • No preview · Article · Nov 2006 · Value in Health
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La anidulafungina es una nueva y eficaz aportación farmacológica para el tratamiento de las micosis invasoras. La anidulafungina tiene un espectro antifúngico que engloba a los hongos patógenos más comunes y especialmente a los géneros Candida y Aspergillus. Su mecanismo de acción se basa en la inhibición de la síntesis de ß-1,3-D-glucano, molécula esencial para la pared fúngica. Este mecanismo tiene como consecuencia dos tipos de acciones: una acción fungicida contra Candida y una acción fungistática contra Aspergillus y otros hongos filamentosos. En este revisión se describe el espectro antifúngico in vitro de anidulafungina tomando como base los datos publicados en los últimos años. Destaca que más del 99% de los aislamientos de Candida son sensibles a concentraciones menores o iguales de 2 µg/ml. También se ha descrito una actividad excelente frente a Aspergillus, Pneumocystis y otros hongos. Sin embargo, su actividad es prácticamente nula contra Cryptococcus y los zigomicetos. Esta excelente actividad antifúngica hace que la anidulafungina sea una indicación terapéutica de primera línea para el tratamiento de las candidemias y candidiasis invasoras en pacientes sin neutropenia.
    Full-text · Article · Jun 2008 · Revista Iberoamericana de Micología
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anidulafungin is a new and very useful pharmacological tool for the treatment of invasive mycoses. The antifungal spectrum of anidulafungin reaches the most common pathogenic fungi. Anidulafungin is especially active against the genera Candida and Aspergillus. Its antifungal mechanism is based on the inhibition of the beta-1,3-D-glucan synthesis, an essential molecule for the cell wall architecture, with different consequences for Candida and Aspergillus, being anidulafungin fungicide for the former and fungistatic for the latter. This review describes the in vitro antifungal spectrum of anidulafungin based in the scientific and medical literature of recent years. We can underline that most than 99% of Candida isolates are susceptible to < or = 2 microg/ml of anidulafungin. MIC are very low (< or =0.125 microg/ml) for most clinical isolates of the species Candida albicans, Candida glabrata, Candida tropicalis and Candida krusei while Candida parapsilosis and Candida guilliermondii isolates are susceptible to anidulafungin concentrations < or = 2 microg/ml. An excellent activity of anidulafungin has been also described against Aspergillus, Pneumocystis and other fungi. However, its activity is very low against Cryptococcus and the Zygomycetes. The excellent activity of anidulafungin has made this antifungal a first line therapeutic indication for candidemia and invasive candidiasis in non-neutropenic patients.
    No preview · Article · Jul 2008 · Revista Iberoamericana de Micología
Show more